Vitamin D Council needs your help...

Tax-deductible!

Together we can end the illness and disease caused by the worldwide epidemic of vitamin D deficiency.

About Vitamin D Council

Contact Vitamin D Council

Sponsor Vitamin D Council

Follow us on:

Vitamin D Products

(off-site)

These companies donate to the Vitamin D Council.

D-Lite, Renew, & SunSplash UV/Tanning Systems
In-Home ZRT Vitamin D Blood Test Kit
Get Premium Quality Vitamin D Supplements at Great Prices
Vitamin D3 Plus™ from Bio-Tech — contains the cofactors Vitamin D needs to work properly.

Vitamin D Research

back to research menu

Melanoma

Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: Association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett. 2009 Oct 8;283(2):222–9.
Serum 25-Hydroxyvitamin D3 Levels Are Associated With Breslow Thickness at Presentation and Survival From Melanoma. J Clin Oncol. 2009 Sep 21.
Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res. 2009 Sep;29(9):3669–74.
Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells. Anticancer Res. 2009 Sep;29(9):3647–58.
The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009 Sep;29(9):3511–36. Review.
Vitamin D receptor variants and the malignant melanoma risk: a population-based study. Cancer Epidemiol. 2009 Aug;33(2):103–7.
Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer. 2009 Jul 15.
Vitamin D and melanoma. Ann Epidemiol. 2009 Jul;19(7):455–61.
Vitamin D intake and melanoma risk. J Invest Dermatol. 2009 Jul;129(7):1598.
A cohort study of vitamin D intake and melanoma risk. J Invest Dermatol. 2009 Jul;129(7):1675–80.
Increased UVA exposures and decreased cutaneous Vitamin D(3) levels may be responsible for the increasing incidence of melanoma. Med Hypotheses. 2009 Apr;72(4):434–43.
Vitamin D and skin cancer: a meta-analysis. Eur J Cancer. 2009 Mar;45(4):634–41. Review.
Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids. 2009 Feb;74(2):218–28.
Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer. 2009 Jan 13;100(1):174–7.
Dietary supplement use in adult cancer survivors. Oncol Nurs Forum. 2009 Jan;36(1):61–8.
Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies. BMC Cancer. 2008 Dec 23;8(1):385.
Risk of prostate, breast and colorectal cancer after skin cancer diagnosis. Int J Cancer. 2008 Dec 15;123(12):2899–901.
Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids. 2008 Nov 6.
Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis. Cancer. 2008 Nov 1;113(9):2398–407.
Are tanning beds "safe"? Human studies of melanoma. Pigment Cell Melanoma Res. 2008 Oct;21(5):517–9.
UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell Melanoma Res. 2008 Oct;21(5):509–16. Review.
Risk of prostate, breast and colorectal cancer after skin cancer diagnosis. Int J Cancer. 2008 Sep 3;123(12):2899–2901.
Sunlight, UV-radiation, vitamin D and skin cancer: how much sunlight do we need? Adv Exp Med Biol. 2008;624:1–15. Review.
Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. Eur J Cancer. 2007 Jul;43(11):1701–12.
Sunlight, skin cancer and vitamin D: What are the conclusions of recent findings that protection against solar ultraviolet (UV) radiation causes 25-hydroxyvitamin D deficiency in solid organ-transplant recipients, xeroderma pigmentosum, and other risk groups? J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):664–7.
An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer. 2007 Mar 1;120(5):1123–8.
A meta-analysis of second cancers after a diagnosis of nonmelanoma skin cancer: Additional evidence that solar ultraviolet-B irradiance reduces the risk of internal cancers. J Steroid Biochem Mol Biol. 2007 Mar;103(3–5):668–74.
Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br J Dermatol. 2007 Feb;156(2):277–82.
Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007 Feb;127(2):276–80.
Vitamin D—an emerging issue in skin cancer control. Implications for public health practice based on the Australian experience. Recent Results Cancer Res. 2007;174:197–204. Review.
Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993–2002. BMC Cancer. 2006 Nov 10;6:264.
The challenge resulting from positive and negative effects of sunlight: how much solar UV exposure is appropriate to balance between risks of vitamin D deficiency and skin cancer? Prog Biophys Mol Biol. 2006 Sep;92(1):9–16. Review.
Does sunlight have a beneficial influence on certain cancers? Prog Biophys Mol Biol. 2006 Sep;92(1):132–9.Review.
Clusterin (CLU) and melanoma growth: CLU is expressed in malignant melanoma and 1,25-dihydroxyvitamin D3 modulates expression of CLU in melanoma cell lines in vitro. Anticancer Res. 2006 Jul–Aug;26(4A):2707–16.
1,25-Dihydroxyvitamin D(3) inhibits tumor necrosis factor-alpha-induced adhesion molecule expression in endothelial cells. Cell Biol Int. 2006 Apr;30(4):365–75.
The Molecular Basis of Vitamin D Receptor and beta-Catenin Crossregulation. Mol Cell. 2006 Mar 17;21(6):799–809.
Variation in incidence and fatality of melanoma by season of diagnosis in new South Wales, Australia. Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):524–6.
Cutaneous melanoma and intervention strategies to reduce tumor-related mortality: what we know, what we don't know, and what we think we know that isn't so. Dermatol Ther. 2006 Jan–Feb;19(1):50–69. Review.
Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers. Mutat Res. 2005 Apr 1;571(1–2):207–19.
Seasonal variation in the diagnosis of cutaneous melanoma and non-cutaneous malignancies: an Italian population-based study. Melanoma Res. 2005 Feb;15(1):69–72.
Sun exposure and mortality from melanoma. J Natl Cancer Inst. 2005 Feb 2;97(3):195–9.
Sunlight and reduced risk of cancer: is the real story vitamin D? J Natl Cancer Inst. 2005 Feb 2;97(3):161–3.
Seasonal variation in the occurrence of cutaneous melanoma in Europe: influence of latitude. An analysis using the eurocare group of registries. Eur J Cancer. 2005 Jan;41(1):126–32.
Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB. 2005;19:1067–1077.
Seasonal variations in the diagnosis of cutaneous melanoma. J Am Acad Dermatol. 2004 May;50(5):679–82.
Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. J Steroid Biochem Mol Biol. 2004 May;89–90(1–5):375–9.
Pigment anomaly caused by calcipotriol in a subject with melanoma. J Eur Acad Dermatol Venereol. 2004 Jan;18(1):113–5.
Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol. 2003 Dec;149(6):1200–6.
Studies on the influence of vitamin D3 metabolites on apoptosis induction in human neoplastic cells. Acta Pol Pharm. 2003 Sep–Oct;60(5):363–6.
Ultraviolet radiation: sun exposure, tanning beds, and vitamin D levels. What you need to know and how to decrease the risk of skin cancer. J Am Osteopath Assoc. 2003 Aug;103(8):371–5. Review.
Dietary factors in the prevention and treatment of nonmelanoma skin cancer and melanoma. Dermatol Surg. 2002 Dec;28(12):1143–52. Review.
Influence of vitamin D3 metabolites on cell proliferation and cytotoxicity of adriamycin in human normal and neoplastic cells. Toxicol In Vitro. 2002 Dec;16(6):663–7.
Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol. 2002 Aug;147(2):197–213. Review.
Delay in the diagnosis of cutaneous melanoma: an analysis of 233 patients. Melanoma Res. 2002 Aug;12(4):389–94.
A non-calcemic sulfone version of the vitamin D(3) analogue seocalcitol (EB 1089): chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin. Bioorg Med Chem. 2001 Sep;9(9):2365–71.
Expression and regulation of parathyroid hormone-related peptide in normal and malignant melanocytes. Am J Physiol Cell Physiol. 2000 Oct;279(4):C1230–8.
Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor. J Cell Biochem. 2000 Apr;78(1):112–20.
Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res. 2000 Feb;6(2):498–504.
Environmental factors in nonmelanoma and melanoma skin cancer. J Epidemiol. 1999 Dec;9(6 Suppl):S102–14. Review.
Skin cancer and solar UV radiation. Eur J Cancer. 1999 Dec;35(14):2003–9. Review.
Positive and negative interaction of 1,25-dihydroxyvitamin D3 and the retinoid CD437 in the induction of human melanoma cell apoptosis. Int J Cancer. 1999 May 5;81(3):467–70.
Novel 19-nor-hexafluoride vitamin D3 analog (Ro 25-6760) inhibits human colon cancer in vitro via apoptosis. Int J Oncol. 1999 May;14(5):979–85.
Does the universal "signal transduction pathway of differentiation" exist? Comparison of different cell differentiation experimental models with differentiation of HL-60 cells in response to 1,25-dihydroxyvitamin D3 Postepy Hig Med Dosw. 1999;53(2):305–13. Review in Polish.
Melanoma is not caused by sunlight. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. Vol. 422, Issue 1, 9 Nov 1998, Pages 113–117.
Differential apoptotic response of human melanoma cells to 1 alpha,25-dihydroxyvitamin D3 and its analogues. Cell Death Differ. 1998 Nov;5(11):946–52.
Down-regulation of laminin-binding integrins by 1 alpha,25-dihydroxyvitamin D3 in human melanoma cells in vitro. Cell Adhes Commun. 1998 Mar;5(2):109–20.
Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res. 1996 Feb 15;61(1):127–33.
Use of vitamins A and D in chemoprevention and therapy of cancer: control of nuclear receptor expression and function. Vitamins, cancer and receptors. Adv Exp Med Biol. 1995;375:1–15.
Seasonal variation in frequency of diagnosis of cutaneous malignant melanoma. Melanoma Res. 1994 Aug;4(4):235–41.
Beneficial effects of sun exposure on cancer mortality. Prev Med. 1993 Jan;22(1):132–40. Review.
Rising trends in melanoma. An hypothesis concerning sunscreen effectiveness. Ann Epidemiol. 1993 Jan;3(1):103–10. Review.
Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society. Pigment Cell Res. 1992;Suppl 2:285–94.
I alpha-25-dihydroxyvitamin D3 increases intracellular free calcium in murine B16 melanoma. Br J Dermatol. 1989 Jan;120(1):21–30.
1,25-Dihydroxyvitamin D3 decreases expression of HLA class II molecules in a melanoma cell line. J Immunol. 1988 Jun 1;140(11):4013–8.
Human melanoma cells: functional modulation by calciotropic hormones. J Invest Dermatol. 1988 Jun;90(6):834–40.
Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987 Jan 1;47(1):21–5.
1,25-Dihydroxyvitamin D3 enhances the growth of tumors in athymic mice inoculated with receptor rich osteosarcoma cells. Biochem Biophys Res Commun. 1986 Sep 30;139(3):1292–8.
1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J Clin Invest. 1986 Aug;78(2):557–66.
Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol. 1986 Jun;86(6):709–14.
Biochemical significance of enhanced activity of fluorinated 1,25-dihydroxyvitamin D3 in human cultured cell lines. Cell Biochem Funct. 1986 Apr;4(2):115–22.
Seasonality of presentation of cutaneous melanoma, squamous cell cancer and basal cell cancer in the Oxford Region. Br J Cancer. 1985 Dec;52(6):893–900.
Regulation of melanin synthesis of B16 mouse melanoma cells by 1 alpha, 25-dihydroxyvitamin D3 and retinoic acid. Cancer Res. 1985 Apr;45(4):1474–8.
Regulation of cell differentiation and tumor promotion by 1 alpha,25 dihydroxyvitamin D3. Carcinog Compr Surv. 1985;10:275–86.
Seasonal patterns in the diagnosis of malignant melanoma of skin and eye in upstate New York. Cancer. 1984 Dec 1;54(11):2587–94.
1 alpha, 25-Dihydroxyvitamin D3 specifically induces its own metabolism in a human cancer cell line. Endocrinology. 1984 Apr;114(4):1225–31.
The synthesis of vitamin D metabolites by human melanoma cells. J Clin Endocrinol Metab. 1983 Sep;57(3):627–31.
Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. Cancer Res. 1983 Sep;43(9):4443–7.
1,25-dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. Cancer Res. 1982 Mar;42(3):856–9.
Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture. Cancer Res. 1982 Mar;42(3):1116–9.
1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology. 1981 Mar;108(3):1083–6.

back to research menu

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Unless otherwise expressly stated, all site content licensed under a Creative Commons License.